ARO MMP7
Alternative Names: ARO-MMP7Latest Information Update: 30 Nov 2022
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antifibrotics; Small interfering RNA
- Mechanism of Action Matrix metalloproteinase 7 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Idiopathic pulmonary fibrosis
Most Recent Events
- 30 Jan 2023 Phase-I/II clinical trials in Idiopathic pulmonary fibrosis in New Zealand(Inhalation) (NCT05537025)
- 19 Aug 2022 Arrowhead Pharmaceuticals plans a phase I/IIa AROMMP7-1001 trial for Idiopathic pulmonary fibrosis (In volunteers) in (Country) (Ref), (NCT ref)
- 17 Aug 2022 Arrowhead files a regulatory application for Idiopathic pulmonary fibrosis in the US and New Zealand